for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-FDA Approves Merck's Keytruda For The Treatment Of Recurrent Or Metastatic Cutaneous Squamous Cell Carcinoma

June 24 (Reuters) - Merck & Co Inc:

* FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF PATIENTS WITH RECURRENT OR METASTATIC CUTANEOUS SQUAMOUS CELL CARCINOMA (CSCC) THAT IS NOT CURABLE BY SURGERY OR RADIATION Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up